Dot gov

Official websites use the Texas HHS logo.
The Texas HHS logo means this is an official website of Texas Health and Human Services.

HTTPS

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

5. Fentanyl (References)

  1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2021. Available at: http://www.clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed December 12, 2023.
  2. DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com.libproxy.uthscsa.edu/. Accessed December 12, 2023.
  3. Fentanyl citrate oral transmucosal lozenge (Actiq®) package insert. Cephalon, Inc. November 2022.
  4. Fentanyl buccal tablet (Fentora®) package insert. Cephalon, Inc. November 2022.
  5. Fentanyl transdermal system package insert. Apotex Corp. July 2023.
  6. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep 2022;71(No. RR-3):1–95.
  7. Mystakidou K, Befon S, Tsilika E, et al: Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinial trial in patients naive to mild or strong opioids. Oncology 2002; 62:9-16.
  8. Vielvoye-Kerkmeer APE, Mattern C, & Uitendaal MP: Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. J Pain Symptom Manage 2000; 19(3):185-192.
  9. Langford R, McKenna F, Ratcliffe S, et al: Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Arthritis Rheum 2006; 54(6):1829-1837.
  10. Choquette D, McCarthy TG, Rodrigues JF, et al: Transdermal fentanyl improves pain control and functionality in patients with osteoarthritis: an open-label Canadian trial. Clin Rheumatol 2008; 27(5):587-595.
  11. Kolasinski SL, Neogi T, Hochberg MC, et al: 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol 2020; 72(2):220-233.
  12. Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020;4(12):2656-2701.
  13. Naloxone hydrochloride (Narcan®) 4 mg/ 0.1 mL nasal spray package insert. HF Acquisition Co LLC, DBA HealthFirst. October 2023.
  14. Naloxone hydrochloride (Kloxxado®) 8 mg/ 0.1 mL nasal spray package insert. Hikma Specialty USA Inc., May 2022.
  15. Naloxone hydrochloride (Zimhi®) 5 mg/ 0.5 mL single-dose pre-filled syringe package insert. USWM, LLC. October 2021.
  16. U.S. Food and Drug Administration. FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder. FDA Drug Safety Communication. Published online July 23, 2020. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-health-care-professionals-discuss-naloxone-all-patients-when-prescribing-opioid-pain. Accessed December 12, 2023.
  17. Texas Pharmacy Association. Texas pharmacist naloxone standing order application. October 2016. Available at: https://www.texaspharmacy.org/page/TXPHARMNALOX. Accessed December 12, 2023.